AEterna Zentaris Inc. (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AEZS Nasdaq 8731 https://www.zentaris.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AEterna Zentaris Inc. (USA)

Aeterna Zentaris Announces Results of Annual Meeting of Shareholders - Jun 21st, 2022 8:01 pm
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program - Jun 13th, 2022 12:00 pm
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference - Jun 9th, 2022 12:00 pm
Here's Why We're Watching Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation - Jun 3rd, 2022 10:58 am
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency - May 25th, 2022 12:00 pm
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference - May 18th, 2022 12:00 pm
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation - May 16th, 2022 12:00 pm
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease - May 12th, 2022 12:05 pm
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook - May 11th, 2022 12:05 pm
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - May 2nd, 2022 12:25 pm
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists - Apr 25th, 2022 12:05 pm
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults - Apr 19th, 2022 12:05 pm
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC - Apr 13th, 2022 2:45 pm
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight - Apr 12th, 2022 12:05 pm
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity - Apr 11th, 2022 12:05 pm
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook - Mar 29th, 2022 12:00 pm
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates - Mar 21st, 2022 9:15 pm
Aeterna Zentaris Says Enrollment In Growth Hormone Deficiency Trial To Continue Into 2023 - Mar 21st, 2022 4:22 pm
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Mar 21st, 2022 12:05 pm
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates - Mar 17th, 2022 12:25 pm